[VOD AVAILABLE] Decoding Her2 testing for targeted therapy in gastric cancer in the era of Precision medicine
Speaker
Dr. Anuradha Sekaran, MD, DNB, MNAMS,
Director & Chief of Pathology at AIG Hospitals
Hyderabad, India
Dr. Anuradha Sekaran, MD, DNB, MNAMS, is the Director & Chief of Pathology at AIG Hospitals, Hyderabad, India. With over 20 years of expertise in diagnostic GI pathology, she is also the Joint Secretary of IAPM Telangana state and Secretary of AIG IMA branch. Renowned for her contributions to oncopathology, hepatic-pancreaticobiliary, and nephropathology, she has published 74 peer-reviewed articles and 4 book chapters. A leader in pathology education and research, Dr. Sekaran also guides the GI Pathology Fellowship program and has received multiple prestigious awards.
Lecture Abstract
HER2 (Human Epidermal Growth Factor Receptor 2) is a gene encoding receptor tyrosine kinase that, when over expressed or amplified, plays a crucial role in cancer cell growth, differentiation and cancer progression. Targeting HER2 with specific therapies can lead to improved outcomes in patients whose tumors exhibit HER2 positivity. Determination of HER2 status is crucial in order to select patients who may benefit from this treatment. They are challenges in HER2 Testing for Gastric Cancer due to tumor heterogeneity and histological variability It’s crucial to consider these variations in HER2 testing and interpretation. The detection methods and the interpretation of immunohistochemistry scoring system will be discussed.
We hoped you have enjoyed the webinar and gained new insights!
May we request your time for a short survey?